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The Hippo pathway is a cellular signalling network, which plays major roles in organ homeostasis
and development [1–5]. However, when this cellular signalling pathway is perturbed, diseases such as
cancer, excessive fibrosis, metabolic disorders and impaired immune responses occur [1–6]. The current
significant interest in the pathway continues to reveal new links between diseases and the Hippo
pathway, as well as to provide new insights into what role the Hippo pathway plays in normal
development, regenerative processes, organ size control [2–5], and cellular homeostasis, including
fundamental processes such as cell size regulation [7,8]. This Special Issue provides an up-to-date
overview of this exciting cellular signalling pathway.
The Hippo pathway is a serine/threonine kinase cascade that mediates the phosphorylation
and, thereby, inactivation of the transcriptional co-regulators YAP and TAZ. A range of scaffolding
proteins plays central roles in the dynamic regulation of this pathway. YAP/TAZ does not bind
DNA directly and, therefore, utilizes transcription factors to mediate its transcriptional response.
Phosphorylated YAP/TAZ is sequestered in the cytoplasm and subsequently does not bind to nuclear
localised transcription factors [1].
In this special issue, Gundogdu and Hergovich authoritatively highlight the Mps one Binder
(MOB) scaffolding proteins as central players. They further emphasize not only the disease relevance
of the precise regulation of the MOBs and their direct involvement in the kinase regulation of the
Hippo pathway, but also the MOBs’ important function in scaffolding other kinase complexes [9].
Next, Huh, Kim, Jeong, and Park analyse the regulation of the TEADs, the main transcription factors
used by YAP/TAZ [10]. This is an exciting area of research that up until recently has been understudied.
Targeting the transcription factors directly, instead of focusing on YAP/TAZ, could be a fertile avenue
to pursue, especially considering the current challenges in targeting the Hippo pathway. Hillmer and
Link then describe how YAP/TAZ modulates the chromatin through TEADs and a range of additional
cofactors [11]. YAP/TAZ-mediated chromatin remodelling is a field that, due to recent technological
advances, has revealed major mechanistic insights into how YAP/TAZ either activates or represses
gene transcription. Hillmer and Link provide a concise overview of these recent developments and
also summarise outstanding questions that need addressing in the years to come [11].
Luo and Yu then highlight the importance of G-protein-coupled receptors (GPCRs) as one of the
main upstream regulators of the Hippo pathway [12]. Their discussion focuses on how mutations [13,14],
as well as altered GPCR activity [13,15], might drive tumourigenesis in multiple tissues via elevated
YAP/TAZ activity. Luo and Yu examine how this GPCR–Hippo axis can be targeted in cancer [12].
Rognoni and Walko (featured on the front page) discuss the importance of YAP/TAZ in skin
physiology, including in wound healing processes [16]. The mammalian skin is a well-structured
organ with distinct cell layers. The skin is therefore an intriguing model organ to study in the
context of the Hippo pathway, as it highlights the importance of the mesoscale organisation and the
context-specific temporal and spatial regulation of YAP/TAZ [16]. Wound healing that is not resolved
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causes excessive fibrotic scarring. Kim, Choi, and Mo follow on and continue the discussion on how
dysregulated YAP/TAZ drives fibrosis in multiple organs and also elaborate on its consequences for
cancer development and its therapeutic implications [17]. Most types of solid tumours have high
YAP/TAZ activity, and the majority of these cancers appear addicted to YAP/TAZ hyperactivity [18,19].
Advanced prostate cancer is one of the leading cancers killing men worldwide. This prevalent cancer
therefore urgently needs improved therapeutics [20]. Omar Salem and I detail the role of the Hippo
pathway in prostate cancer. We interrogate how impaired Hippo pathway activity contributes to this
deadly disease [21].
Tumour growth needs additional blood supply, as cancer cells require both nutrients and oxygen.
Malignant progression is consequently often paralleled by an angiogenic switch, where the vasculature
transitions from a quiescent to a proliferative state [22]. In addition, angiogenesis also facilitates
metastasis. The role and importance of angiogenesis in cancer development and growth is therefore
well established [22]. Angiogenesis is also important in a range of healthy processes, such as embryonic
development and wound healing. Azad, Ghahremani, and Yang highlight YAP/TAZ’s critical roles in
endothelial cells during angiogenesis not only in healthy but also in pathological processes, such as
tumour vascular mimicry [23]. Brandt, North, and Link take advantage of the recent technical
developments using CrispR to generate lats2 knockout zebrafish. Interestingly, fish with somatic
loss of function mutations of lats2, but not lats1, develop peripheral nerve sheath tumours [24].
The comparative low cost of maintaining zebrafish, the relative ease of genetic manipulations, the
fast embryonic development, and the ability to carry out robust drug screens [25] will likely continue
to make this a powerful model organism for research aiming at obtaining further fundamental
insights into hyperactive-YAP/TAZ-driven human disease. Finally, Yamauchi and Moroishi [26] give an
up-to-date and commanding overview of the Hippo pathway’s role in the adaptive immune system [27].
Upstream core kinase components play pivotal roles in adaptive immunity and in both pro- and
anticancer immune responses. Interestingly, these processes occur both independently of as well as
through YAP/TAZ regulation [27–30].
The pioneering discovery of the Hippo pathway in Drosophila melanogaster [31] and the subsequent
recognition that the major pathway components are greatly conserved in mammals have firmly
established the need for both powerful model organisms and in vitro cellular model systems as means
to obtain detailed insights into fundamental biological processes driven by the Hippo pathway [1–6].
Recent discoveries reveal that a wide range of diseases are driven by dysfunctional Hippo pathway
activity and drive the continued interest in the pathway [1–6]. The articles in this Special Issue written
by leading experts cover a wide range of diseases that are driven by perturbed Hippo pathway activity.
Research into the Hippo pathway is a fascinating field that continues to hold great promise, and which
will undoubtedly produce further major discoveries in years to come.
Acknowledgments: I want to especially thank the contributors to the Special Issue as well as to acknowledge
the expert reviewers who reviewed submissions in a timely, fair, and constructive manner. Ongoing work in the
Gram Hansen Lab is funded by a University of Edinburgh Chancellor’s Fellowship and the Worldwide Cancer
Research charity.
References
1. Hansen, C.G.; Moroishi, T.; Guan, K.-L. YAP and TAZ: A nexus for Hippo signaling and beyond.Trends Cell Boil.
2015, 25, 499–513. [CrossRef] [PubMed]
2. Moya, I.M.; Halder, G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev.
Mol. Cell Biol. 2019, 20, 211–226. [CrossRef] [PubMed]
3. Davis, J.R.; Tapon, N. Hippo signalling during development. Development 2019, 146, dev167106. [CrossRef]
[PubMed]
4. Zheng, Y.; Pan, D. The Hippo Signaling Pathway in Development and Disease. Dev. Cell 2019, 50, 264–282.
[CrossRef]
Cells 2019, 8, 1179 3 of 4
5. Ma, S.; Meng, Z.; Chen, R.; Guan, K.-L. The Hippo Pathway: Biology and Pathophysiology. Annu. Rev. Biochem.
2019, 88, 577–604. [CrossRef]
6. Koo, J.H.; Guan, K.L. Interplay between YAP/TAZ and Metabolism. Cell Metab. 2018, 28, 196–206. [CrossRef]
7. Hansen, C.G.; Ng, Y.L.D.; Lam, W.-L.M.; Plouffe, S.W.; Guan, K.-L. The Hippo pathway effectors YAP and
TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Res. 2015, 25, 1299–1313.
[CrossRef]
8. Tumaneng, K.; Schlegelmilch, K.; Russell, R.C.; Yimlamai, D.; Basnet, H.; Mahadevan, N.; Fitamant, J.;
Bardeesy, N.; Camargo, F.D.; Guan, K.-L. YAP mediates crosstalk between the Hippo and PI(3)K–TOR
pathways by suppressing PTEN via miR-29. Nat. Cell Biol. 2012, 14, 1322–1329. [CrossRef]
9. Gundogdu, R.; Hergovich, A. MOB (Mps one Binder) Proteins in the Hippo Pathway and Cancer. Cells 2019,
8, 569. [CrossRef]
10. Huh, H.D.; Kim, D.H.; Jeong, H.-S.; Park, H.W. Regulation of TEAD Transcription Factors in Cancer Biology.
Cells 2019, 8, 600. [CrossRef]
11. Hillmer, R.E.; Link, B.A. The Roles of Hippo Signaling Transducers Yap and Taz in Chromatin Remodeling.
Cells 2019, 8, 502. [CrossRef] [PubMed]
12. Luo, J.; Yu, F.-X. GPCR-Hippo Signaling in Cancer. Cells 2019, 8, 426. [CrossRef] [PubMed]
13. Yu, F.-X.; Zhao, B.; Panupinthu, N.; Jewell, J.L.; Lian, I.; Wang, L.H.; Zhao, J.; Yuan, H.; Tumaneng, K.; Li, H.;
et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150, 780–791.
[CrossRef] [PubMed]
14. Yu, F.-X.; Luo, J.; Mo, J.-S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al.
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25, 822–830.
[CrossRef] [PubMed]
15. Liu, G.; Yu, F.-X.; Kim, Y.C.; Meng, Z.; Naipauer, J.; Looney, D.J.; Liu, X.; Gutkind, J.S.; Mesri, E.A.;
Guan, K.-L. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo
pathway. Oncogene 2015, 34, 3536–3546. [CrossRef] [PubMed]
16. Rognoni, E.; Walko, G. The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin.
Cells 2019, 8, 411. [CrossRef] [PubMed]
17. Kim, C.-L.; Choi, S.-H.; Mo, J.-S. Role of the Hippo Pathway in Fibrosis and Cancer. Cells 2019, 8, 468.
[CrossRef]
18. Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP and TAZ: a signalling hub of the tumour microenvironment.
Nat. Rev. Cancer 2019, 19, 454–464. [CrossRef]
19. Moroishi, T.; Hansen, C.G.; Guan, K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 2015,
15, 73–79. [CrossRef]
20. Wang, G.; Zhao, D.; Spring, D.J.; Depinho, R.A. Genetics and biology of prostate cancer. Genome Res. 2018,
32, 1105–1140. [CrossRef]
21. Salem, O.; Hansen, C.G. The Hippo Pathway in Prostate Cancer. Cells 2019, 8, 370. [CrossRef] [PubMed]
22. De Palma, M.; Biziato, D.; Petrova, T.V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer
2017, 17, 457–474. [CrossRef] [PubMed]
23. Azad, T.; Ghahremani, M.; Yang, X. The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry.
Cells 2019, 8, 407. [CrossRef] [PubMed]
24. Brandt, Z.J.; North, P.N.; Link, B.A. Somatic Mutations of lats2 Cause Peripheral Nerve Sheath Tumors
in Zebrafish. Cells 2019, 8, 972. [CrossRef]
25. Wiley, D.S.; Redfield, S.E.; Zon, L.I. Chemical screening in zebrafish for novel biological and therapeutic
discovery. Methods Cell Biol. 2017, 138, 651–679.
26. Spotlight on early-career researchers: an interview with Toshiro Moroishi. Commun. Boil. 2019, 2, 1–2.
27. Yamauchi, T.; Moroishi, T. Hippo Pathway in Mammalian Adaptive Immune System. Cells 2019, 8, 398.
[CrossRef] [PubMed]
28. Moroishi, T.; Hayashi, T.; Pan, W.-W.; Fujita, Y.; Holt, M.V.; Qin, J.; Carson, D.A.; Guan, K.-L. The Hippo
Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell 2016, 167, 1525–1539.e17. [CrossRef]
29. Wu, A.; Deng, Y.; Liu, Y.; Lu, J.; Liu, L.; Li, X.; Liao, C.; Zhao, B.; Song, H. Loss of VGLL4 suppresses tumor
PD-L1 expression and immune evasion. Embo J. 2019, 38, e99506. [CrossRef]
Cells 2019, 8, 1179 4 of 4
30. Liu, H.; Dai, X.; Cao, X.; Yan, H.; Ji, X.; Zhang, H.; Shen, S.; Si, Y.; Zhang, H.; Chen, J.; et al. PRDM4 mediates
YAP-induced cell invasion by activating leukocyte-specific integrin beta2 expression. EMBO Rep. 2018, 19,
e45180. [CrossRef]
31. Gokhale, R.; Pfleger, C.M. The Power of Drosophila Genetics: The Discovery of the Hippo Pathway.
Methods Mol. Biol. 2019, 1893, 3–26. [PubMed]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
